Many progresses for the treatment of multiple myeloma have been made since last decade.The application of novel target agents has brought the treatment of multiple myeloma into a new era.The outcomes of multiple myeloma have also been greatly improved with mechanism-based combinations of various agents.It is emphasized that clinicians should better understand the biological characteristics of myeloma cells and the anti-myeloma mechanisms underlined.In this review,the author will review the current status and make a prospective discussion in this field. Key words: Multiple myeloma; Immunosuppressive agents; Protease inhibitor
Jamie CavenaghHeather Oakerveeon behalf of the UK Myeloma Forum and The BCSH Haematology/Oncology Task Forces
Brian G.M. DurieSydney E. Salmon
Lena‐Marie RängerUlrich PreißingerThomas Grützner